Article ID Journal Published Year Pages File Type
6242390 Respiratory Medicine 2014 6 Pages PDF
Abstract
Our results suggest that infliximab adds minimal potential benefit to corticosteroids for pulmonary sarcoidosis at doses above 15-20 mg/day of prednisone.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Pulmonary and Respiratory Medicine
Preview
The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial
Authors
, , , , ,